These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1054 related articles for article (PubMed ID: 9084964)

  • 1. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA; Cameron NE; Hohman TC
    J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
    FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of defective peripheral nerve conduction velocity, nutritive endoneurial blood flow, and oxygenation by a novel aldose reductase inhibitor, WAY-121,509, in streptozotocin-induced diabetic rats.
    Cameron NE; Cotter MA; Dines KC; Hohman TC
    J Diabetes Complications; 1996; 10(1):43-53. PubMed ID: 8639974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats.
    Cameron NE; Cotter MA; Hohman TC
    Diabetologia; 1996 Feb; 39(2):172-82. PubMed ID: 8635669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.
    Cameron NE; Cotter MA; Dines KC; Maxfield EK; Carey F; Mirrlees DJ
    Diabetologia; 1994 Jul; 37(7):651-63. PubMed ID: 7958535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats.
    Kador PF; Inoue J; Secchi EF; Lizak MJ; Rodriguez L; Mori K; Greentree W; Blessing K; Lackner PA; Sato S
    Exp Eye Res; 1998 Aug; 67(2):203-8. PubMed ID: 9733586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced nerve blood flow in diabetic rats: relationship to nitric oxide production and inhibition of aldose reductase.
    Tomlinson DR; Dewhurst M; Stevens EJ; Omawari N; Carrington AL; Vo PA
    Diabet Med; 1998 Jul; 15(7):579-85. PubMed ID: 9686698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
    Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K; Naruse K; Nakashima E; Sakamoto N
    J Pharmacol Exp Ther; 1996 Jan; 276(1):49-55. PubMed ID: 8558455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study.
    Obrosova IG; Fathallah L
    Diabetologia; 2000 Aug; 43(8):1048-55. PubMed ID: 10990083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
    Ho EC; Lam KS; Chen YS; Yip JC; Arvindakshan M; Yamagishi S; Yagihashi S; Oates PJ; Ellery CA; Chung SS; Chung SK
    Diabetes; 2006 Jul; 55(7):1946-53. PubMed ID: 16804062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased nerve polyol levels in experimental diabetes and their reversal by Sorbinil.
    Whiting PH; Ross IS
    Br J Exp Pathol; 1988 Oct; 69(5):697-702. PubMed ID: 3143396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
    Gillon KR; Hawthorne JN; Tomlinson DR
    Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
    Hara T; Nakamura J; Koh N; Sakakibara F; Hamada Y; Sasaki H; Naruse K; Nakashima E; Takeuchi N; Inukai S
    J Lab Clin Med; 1995 Dec; 126(6):541-7. PubMed ID: 7490513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats.
    Nakamura J; Koh N; Sakakibara F; Hamada Y; Hara T; Sasaki H; Chaya S; Komori T; Nakashima E; Naruse K; Kato K; Takeuchi N; Kasuya Y; Hotta N
    J Pharmacol Exp Ther; 1998 Dec; 287(3):897-902. PubMed ID: 9864270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered neuroexcitability in experimental diabetic neuropathy: effect of acetyl-L-carnitine.
    Malone JI; Lowitt S; Corsico N; Orfalian Z
    Int J Clin Pharmacol Res; 1992; 12(5-6):237-41. PubMed ID: 1301404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sorbitol dehydrogenase deficiency on nerve conduction in experimental diabetic mice.
    Ng TF; Lee FK; Song ZT; Calcutt NA; Lee AY; Chung SS; Chung SK
    Diabetes; 1998 Jun; 47(6):961-6. PubMed ID: 9604875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.